In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study to evaluate the safety and efficacy of Regeneron’s REGN2810 and Inovio’s INO-5401 combination therapy for the treatment of individuals with newly-diagnosed glioblastoma multiforme.
In June 2017, the European Commission (or EC) approved marketing authorization for Regeneron’s and Sanofi’s (SNY) Kevzara and methotrexate combination for the treatment of moderately to severely active rheumatoid arthritis (or RA) in adult individuals who hadn’t adequately responded to or who were intolerant to disease-modifying anti-rheumatic arthritis (or DMARDs). The EC has also approved the usage of Kevzara as a monotherapy if treatment with methotrexate is unsuitable.
In July 2017, the European Medicine Agency’s (or EMA) Committee for Medicinal Products for Human Use (or CHMP) recommended a positive opinion for the marketing authorization of Regeneron Pharmaceuticals’ and Sanofi’s Dupixent in Europe for the treatment of adult individuals with moderate to severe atopic dermatitis.
Regeneron Pharmaceuticals’ revenue growth could boost the share price of the VanEck Vectors Biotech ETF (BBH). BBH invests ~4.8% of its total portfolio holdings in Regeneron Pharmaceuticals.
Twenty-four analysts were tracking Regeneron Pharmaceuticals in July 2017. Of this total, seven analysts recommended “strong buys” on the stock, while four recommended “buys.” Thirteen analysts recommended “holds, ” and none recommended any form of a “sell.”
Around 46% of the analysts following Regeneron Pharmaceuticals in July 2017 suggested some form of a “buy” on its stock.
Twenty-seven analysts were analyzing Biogen (BIIB) in July 2017. Around ~63% of these analysts recommended some form of a “buy” on the stock. Ten analysts suggested “holds,” and none suggested any form of a “sell.”
Twenty-four analysts were analyzing Amgen (AMGN) in July 2017. Four analysts recommended “strong buys” and six analysts recommended “buys” on the stock. Fourteen analysts recommended “holds,” and none recommended “sells” or “strong sells” on the stock. Around ~42% of analysts recommended some form of a “buy” on Amgen in July 2017.